- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Cancers Expressing HER-2 and/or CEA in United States
Total 1286 results
-
AIRx Health, Inc.Stanford UniversityNot yet recruitingHypertension | Stroke (CVA) or TIAUnited States
-
AstraZenecaCompletedER+ HER2- Advanced Breast CancerUnited States, United Kingdom, Korea, Republic of
-
University of ChicagoNot yet recruitingBreast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of BreastUnited States
-
Jennifer Lee Caswell-JinNational Cancer Institute (NCI); QED Therapeutics, Inc.TerminatedBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Merrimack PharmaceuticalsTerminatedStomach Cancer | Gastroesophageal Junction Cancer | HER-2 Gene Amplification | Esophagus CancerUnited States
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedAdvanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)United States, Belgium, Canada, Italy, Spain, United Kingdom
-
University of UtahCompletedNewly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast CancerUnited States
-
University of Wisconsin, MadisonContext Therapeutics Inc.TerminatedMetastatic Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerUnited States, Spain, United Kingdom
-
BeiGeneRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...Australia, United States
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Abramson Cancer Center at Penn MedicineRecruitingBreast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | ER Positive Breast CancerUnited States
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Sarah Sammons, MDDaiichi SankyoRecruitingBreast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast CancerUnited States
-
Jazz PharmaceuticalsActive, not recruitingHER2+/HR+ Breast CancerUnited States, Spain, Canada
-
AstraZenecaCompletedHER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 MutationsItaly, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
-
MacroGenicsCompletedHER-2 Positive Breast Cancer | Metastatic NeoplasmUnited States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Syndax PharmaceuticalsTerminatedBreast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
OncoSec Medical IncorporatedCompletedER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
SynDevRx, Inc.RecruitingMetastatic Breast Cancer | HR+/HER2-negative Breast CancerUnited States
-
Ana C Garrido-Castro, MDMerck Sharp & Dohme LLC; Gilead SciencesActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | HR-Positive Breast CancerUnited States
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Massachusetts General HospitalGilead SciencesRecruitingTriple Negative Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast CancerUnited States
-
Monte Rosa Therapeutics, IncRecruitingNSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast CancerUnited States, Canada
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Carisma Therapeutics IncActive, not recruitingAdenocarcinoma | Stomach Neoplasms | Cancer | Breast Cancer | Head and Neck Cancer | Carcinoma, Hepatocellular | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Carcinoma, Transitional Cell | Breast Neoplasm | Prostate Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer and other conditionsUnited States
-
UNC Lineberger Comprehensive Cancer CenterNovartis PharmaceuticalsCompletedHER-2 Positive Breast CancerUnited States
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
Dana-Farber Cancer InstitutePfizerCompletedHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor (HR)-Positive Breast CancerUnited States
-
AstraZenecaQuotient SciencesCompletedER-positive, HER2-negative Breast CancerUnited Kingdom
-
Imperial College LondonMedical Research Council; ECMCRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited Kingdom
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingMetastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast CancervUnited States
-
Daiichi SankyoCompletedHER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
University of WashingtonNovo Nordisk A/SNot yet recruitingDiabetes Mellitus, Type 2 | Stroke (CVA) or Transient Ischemic AttackUnited States
-
Royal Marsden NHS Foundation TrustPfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaboratorsRecruitingHER2-negative Breast Cancer | ER+ Breast CancerUnited Kingdom, France
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
University of WashingtonAbbVieNo longer availableTriple-Negative Breast Cancer | Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic MutationUnited States
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
Janssen Research & Development, LLCCompletedPostmenopausal | Metastatic ER+ Her2- Breast CancerUnited States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
-
AstraZenecaCompletedPostmenopausal Women With ER+ HER2- Primary Breast CancerGermany, United Kingdom
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
AstraZenecaRecruitingER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)United Kingdom, Korea, Republic of, Australia, United States, Spain
-
Northwestern UniversityActive, not recruitingCardiovascular Abnormalities | HER2 Positive Breast CancerUnited States
-
AdaptimmuneActive, not recruitingHepatocellular Cancer | AFP Expressing TumorsUnited States, United Kingdom, France, Spain
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
PfizerCompletedHR+/HER2- Locally Advanced, Metastatic Breast CancerUnited Kingdom
-
Seagen Inc.CompletedHER2 Positive Metastatic Breast CancersUnited States